

# **8<sup>th</sup> Northeast Regional Hematology/Oncology Pharmacists Symposium**

## **Boston Marriott Burlington** **Hotel & Conference Center**

**One Burlington Mall Road, Burlington, MA 01803**

**781-229-6565**

## **October 17 & 18, 2014**

- ***Earn up to 12 Contact Hours (1.2 CEUs)***  
***Includes 2 hours of Law Credits***
- ***Sessions are individually accredited***
- ***Network with industry professionals***
- ***Breakfast, lunch, welcome cocktail reception and dinner***

### **Association Sponsors:**



Association of Community Cancer Centers



Please check off programs you will attend – Exhibit Hall opens at 9:45 a.m.

## Friday, October 17, 2014

- ☐ 9:45 a.m. - 10:45 a.m. Registration & Exhibitor Pavilion
- ☐ 10:45 a.m. - 11:00 a.m. Opening Remarks
- ☐ 11:00 a.m. - 12:00 p.m. Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents
- ☐ 12:00 p.m. - 1:00 p.m. Buffet Lunch, Exhibitor Pavilion
- ☐ 1:00 p.m. - 2:00 p.m. Expanding Options for Treatment in Non Hodgkin Lymphoma:  
Progress Across Multiple Histopathologic Subtypes
- ☐ 2:30 p.m. - 3:30 p.m. Treating and Recognizing Infections in the Immunocompromised  
Cancer Patient
- ☐ 4:00 p.m. - 5:00 p.m. Improving Compounding Practices while Protecting Healthcare  
Workers Handling Hazardous Drugs (LAW)
- ☐ 5:00 p.m. - 6:00 p.m. Welcome Reception for Attendees and Exhibitors
- ☐ 6:00 p.m. - 7:00 p.m. Buffet Dinner
- ☐ 7:00 p.m. - 8:00 p.m. An Update of HER2-Directed Therapies for Patients with HER2-Positive  
Breast Cancer in the Neoadjuvant and Adjuvant Settings

## Saturday, October 18, 2014

- ☐ 7:00 a.m. - 7:45 a.m. Registration & Buffet Breakfast
- ☐ 7:45 a.m. - 8:45 a.m. Practical Issues with New Targeted Therapies for Cancer
- ☐ 9:00 a.m. - 10:00 a.m. How We Treat Multiple Myeloma Patients with Renal Dysfunction
- ☐ 10:15 a.m. - 11:15 a.m. Managing Cancer and Thrombosis: Recent Advances and Ongoing Challenges
- ☐ 11:30 a.m. - 12:30 p.m. Chronic Lymphocytic Leukemia (CLL): A Review of New and Emerging  
Treatment Options
- ☐ 12:30 p.m. - 1:30 p.m. Buffet Lunch
- ☐ 1:30 p.m. - 2:30 p.m. Pharmacotherapy of Malignant Melanoma
- ☐ 2:35 p.m. - 3:35 p.m. Update on Advanced Non-Small Cell Lung Cancer: Focus on Targeted Therapies
- ☐ 3:40 p.m. - 4:40 p.m. Biosimilar Regulation and Integration into the Medication Use Process (LAW)

**Credits:** Earn up to 12 Contact Hours (1.2 CEUs)

**Costs:** 2 Days: \$120 Members\*      1-Day: \$95 Members\*  
                 \$140 Non-members      \$110 Non-members

*\*MSHP, ONS NH/VT, ONS Boston, HOPA, ACCC*

Fee includes credits, handouts plus breakfasts, lunches, all day refreshments,  
welcome cocktail reception, and dinner.

**Overnight Room Reservations:** Secure your reservations by 9/24/14. Call 781-229-6565  
or 800-229-9290 and mention NEHOPS for a special rate of \$149.00/night



☐ Ms.    ☐ Mr.    ☐ Pharmacist    ☐ Nurse    ☐ Other

Member \_\_\_\_\_ Lic # \_\_\_\_\_

NABP e-profile # \_\_\_\_\_ Birth Date: MM/DD \_\_\_\_\_

Name \_\_\_\_\_

Home Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Tel. \_\_\_\_\_

Email \_\_\_\_\_

Employer Name \_\_\_\_\_

Practice Setting:    ☐ Health Systems/Hospital    ☐ Community/Retail    ☐ MC  
                                 ☐ Specialty    ☐ LTC    ☐ Academic    ☐ Other

### PAYMENT INFORMATION

☐ Check or Money Order made payable to: American Health Resources, Inc.

☐ Charge my Credit Card    ☐ Visa    ☐ MC    ☐ AmEx    ☐ Discover

Acct. # \_\_\_\_\_ CVC \_\_\_\_\_

Expiration \_\_\_\_\_ Signature \_\_\_\_\_

~ Register by Mail, Fax, Internet or Phone ~

American Health Resources, Inc., 130 Liberty St., Suite 13A, Brockton, MA 02301  
Tel. 508-588-7700 • Fax 508-588-7701 • [www.AHRevents.com](http://www.AHRevents.com)

## Objectives:

Participants will be able to demonstrate clinical knowledge and ability to counsel patients in the areas of: RCC, NSCLC, Melanoma, Breast Cancer, Leukemia, Multiple Myeloma, Neutropenia, Anticoagulation, Non-Hodgkin Lymphoma, Adherence, Biosimilars, Hazardous Medication.

Friday, October 17, 2014

**Opening Remarks • 10:45 a.m. – 11:00 a.m.**

**Seminar 1 • 11:00 a.m. – 12:00 p.m.**

### **Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents**

**Presenter:** Patrick Medina, PharmD, BCOP; Associate Professor, The University of Oklahoma College of Pharmacy

#### **Learning Objectives:**

- Outline the pathophysiology of RCC and how this impacts drug selection
- Review the use of targeted agents in the adjuvant treatment of RCC
- Analyze the trial data to make appropriate first-line treatment recommendations for metastatic RCC
- Given patient specific information select appropriate medications to treat metastatic RCC; including the appropriate sequencing of agents for patients who have progressed on initial therapy
- Describe the mechanism of action, adverse reactions, and monitoring parameters of targeted agents used to treat RCC

ACPE UPN: 0280-0000-14-033-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

**Seminar 2 • 1:00 p.m. – 2:00 p.m.**

### **Expanding Options for Treatment in Non Hodgkin Lymphoma: Progress Across Multiple Histopathologic Subtypes**

**Presenter:** Christopher A. Fausel, PharmD, MHA, BCOP; Clinical Manager, Oncology Pharmacy, Indiana University Health; Chair, Hoosier Oncology Group

#### **Learning Objectives:**

- Identify prominent histopathologic subtypes of non-Hodgkin lymphoma and their relative significance for treatment
- Discuss state of the art treatment options for diffuse large B-cell, follicular, mantle-cell, cutaneous and peripheral T-cell and anaplastic large-cell non-Hodgkin lymphoma
- Articulate the emerging role of targeted molecular therapies into the treatment paradigm of non-Hodgkin lymphoma and how pharmacists can ensure appropriate supportive care for patients during treatment

ACPE UPN: 0280-0000-14-034-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

**Seminar 3 • 2:30 p.m. – 3:30 p.m.**

### **Treating and Recognizing Infections in the Immunocompromised Cancer Patient**

**Presenter:** David Frame, PharmD; Clinical Hematology/Oncology/BMT Specialist, Assistant Professor, University of Michigan

#### **Learning Objectives:**

- Identify the signs of fungal and viral infections and develop an appropriate treatment plan
- Discuss current guidelines on how to prevent infection in patients who are neutropenic but not febrile
- Design an appropriate prophylaxis and empiric therapy plan for neutropenic fever

ACPE UPN: 0280-0000-14-035-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

**Seminar 4 • 4:00 p.m. – 5:00 p.m.**

### **Improving Compounding Practices While Protecting Healthcare Workers Handling Hazardous Drugs (LAW)**

**Presenter:** Eric Kastango, MBA, RPh, FASHP; President & CEO, Clinical IQ, LLC Florham Park, NJ

#### **Learning Objectives:**

- Describe the current regulatory environment in the Commonwealth of Massachusetts for pharmacies that compound sterile medications
- Discuss the major proposed requirements of the new USP hazardous drug chapter
- Describe the various state and national initiatives designed to protect healthcare workers handling hazardous drugs
- Describe risk mitigation strategy to provide safe compounded medication while protecting healthcare workers handling hazardous drugs

ACPE UPN: 0280-0000-14-036-L03-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

**Seminar 5 • 7:00 p.m. – 8:00 p.m.**

**An Update of HER2-Directed Therapies for Patients with HER2-Positive Breast Cancer in the Neoadjuvant and Adjuvant Settings**

**Presenter:** Chad Barnett, PharmD, BCOP; Clinical Pharmacy Specialist, Breast Oncology Division of Pharmacy, University of Texas M. D. Anderson Cancer Center, Houston, Texas

**Learning Objectives:**

- Compare the mechanisms of action, rationale and efficacy of HER2-directed therapies for patients with HER2-positive breast cancer
- Create a treatment and monitoring plan for patients with HER2-positive breast cancer in the neoadjuvant and adjuvant settings
- Identify novel therapies or regimens under investigation for patients with HER2-positive breast cancer in the neoadjuvant and adjuvant settings

ACPE UPN: 0280-0000-14-037-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

**Saturday, October 18, 2014**

**Seminar 6 • 7:45 a.m. – 8:45 a.m.**

**Practical Issues with New Targeted Therapies for Cancer**

**Presenter:** Sarah L. Scarpace, PharmD, MPH, BCOP; Assistant Dean for Pharmacy Professional Affairs, Associate Professor, Pharmacy Practice Albany College of Pharmacy and Health Sciences

**Learning Objectives:**

- Describe evidence-based consequences of nonadherence
- Evaluate theoretical drug interactions for clinical significance
- Recognize areas which can affect therapeutic outcomes such as handling & storage, specialty pharmacy distribution, and unique administration requirements

ACPE UPN: 0280-0000-14-038-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

**Seminar 7 • 9:00 a.m. - 10:00 a.m.**

**How We Treat Multiple Myeloma Patients with Renal Dysfunction**

**Presenter:** R. Donald Harvey, PharmD, FCCP, BCOP; Associate Professor, Hematology/Medical Oncology, Director, Phase 1 Clinical Trials Section, Winship Cancer Institute of Emory University

**Learning Objectives:**

- Describe the pathophysiology and clinical sequelae of myeloma-induced renal disease
- Discuss the use of anti-myeloma therapies and supportive care in patients with reduced renal function
- Review patient outcomes data in those with renal dysfunction in initial treatment, stem cell transplant, and relapsed/refractory settings

ACPE UPN: 0280-0000-14-039-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

**Seminar 8 • 10:15 a.m.-11:15 a.m.**

**Managing Cancer and Thrombosis: Recent Advances and Ongoing Challenges**

**Presenter:** John Fanikos, RPh, MBA; Assistant Director of Pharmacy, Brigham & Women's Hospital; Assistant Clinical Professor of Pharmacy, Massachusetts College of Pharmacy and Health Sciences and Northeastern University Bouve College of Health Sciences, Boston, MA

**Learning Objectives:**

- Discuss the link between cancer and thrombosis
- Develop strategies for risk-directed prophylaxis against venous thromboembolism (VTE) in patients with cancer, using FDA-indicated and approved agents
- Describe how to risk stratify patients undergoing cancer surgery, and implement ACCP-mandated pharmacologic and non-pharmacologic measures aimed at VTE prevention
- Review landmark clinical trials focusing on DVT prophylaxis in patients with cancer.
- Explain how to appropriately use the range of pharmacologic options available for thrombosis management in patients with malignancy

ACPE UPN: 0280-0000-14-040-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)





### Seminar 9 • 11:30 a.m. - 12:30 p.m.

#### **Chronic Lymphocytic Leukemia (CLL): A Review of New and Emerging Treatment Options**

**Presenter:** Ali McBride PharmD, MS, BCPS; Clinical Coordinator Hematology/Oncology, The University of Arizona Cancer Center, Tucson, AZ

#### **Learning Objectives:**

- Summarize current treatment options for the treatment of CLL, including treatment outcomes and side effect profiles
- Interpret new data on novel agents and therapeutic approaches with potential importance in the treatment of patients with chronic lymphocytic leukemia
- Review emerging treatment options for CLL

ACPE UPN: 0280-0000-14-041-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

### Seminar 10 • 1:30 p.m. 2:30 p.m.

#### **Pharmacotherapy of Malignant Melanoma**

**Presenter:** Lew Iacovelli, BS, PharmD, BCOP, CPP; Oncology Pharmacy Manager, Clinical Pharmacist Practitioner, Clinical Hematology-Oncology Specialist, Cone Health Cancer Center, Greensboro, NC

#### **Learning Objectives:**

- Discuss the indications and use of recently approved agents used in the treatment of melanoma
- Illustrate methods for monitoring and managing toxicity in patients receiving recently approved agents used in the treatment of melanoma
- Appraise ongoing clinic trial data with these newer agents with respect to their place as therapy options for patients with melanoma

ACPE UPN: 0280-0000-14-042-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

### Seminar 11 • 2:35 p.m. - 3:35 p.m.

#### **Update on Advanced Non-Small Cell Lung Cancer: Focus on Targeted Therapies**

**Presenter:** Val R. Adams, PharmD, BCOP, FCCP; Associate Professor, Pharmacy Program Director, PGY2, Specialty Residency, Hematology/Oncology, University of Kentucky College of Pharmacy, Lexington, KY

#### **Learning Objectives:**

- Recognize the therapeutic role for EGFR inhibitors, VEGF inhibitors, and PD1 inhibitors for advanced non-small cell lung cancer
- Recommend appropriate toxicity prevention, monitoring, and treatment for select novel agents in each therapeutic class
- Identify targetable pathways where drug therapy is currently being investigated

ACPE UPN: 0280-0000-14-043-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

### Seminar 12 • 3:40 p.m.- 4:40 p.m.

#### **Biosimilar Regulation and Integration into the Medication Use Process (LAW)**

**Presenter:** Edward Li, PharmD, BCOP; Associate Professor, Pharmacy Practice, University of New England College of Pharmacy, Portland, ME

#### **Learning Objectives:**

- Describe regulations that allow for the development of biosimilars, including the FDA evaluation and approval process
- Compare and contrast the regulatory and scientific principles for the development of biosimilar products versus generic small molecule drugs
- Evaluate how biosimilar legislative efforts at the state level will impact the practice of pharmacy.
- Formulate a strategy to incorporate biosimilars into the medication use process

ACPE UPN: 0280-0000-14-044-L03-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)



American Health Resources, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

**Nurses:** American Health Resources, Inc. is approved by the California Board of Registered Nursing, Provider # CEP 14254 and approved this program for 1.0 contact hour for each 1 hour session completed. Please check with licensing board to verify credits can be claimed in your state.

To receive credit, participants must fully attend each session as well as pass in a completed signature verification form with NAPB e-profile number and birth date information (No partial credit will be given). Participants can earn Continuing Pharmacy Education credits for this program by logging onto the website <https://ce.ahrevents.com/> and completing the evaluation form for session(s) attended within 30 days of session date. After completion of the activity evaluation, your continuing pharmacy education credit is automatically reported to CPE Monitor where a certificate of credit can be printed. Please allow up to 48 hours for credit to be available on the CPE Monitor. Participant names will be checked against program attendance sheets for verification of attendance.

**\*Only Certificates of Credit issued from CPE Monitor are valid in the US\* \* CPE Monitor will not accept credits after 60 days from the session date\***

All participants will have the opportunity to evaluate the educational session and presenter as well as the ability to identify their future educational needs. All commercial support received for this conference will be disclosed at the start of the event.

American Health Resources, Inc.  
130 Liberty St., Suite 13A  
Brockton, MA 02301

PRST STD  
U.S. Postage  
**PAID**  
CCP&DF  
02571  
Permit 3



**8<sup>th</sup> Northeast Regional  
Hematology/Oncology  
Pharmacists Symposium**

**October 17 & 18, 2014**

**Boston Marriott Burlington**

*This programming has been designed to meet the educational needs of pharmacists, nurses and other interested healthcare professionals specializing in hematology/oncology practice.*



Like us on Facebook!

<http://www.facebook.com/pages/American-Health-Resources-Inc/347292468615650>